Cara Therapeutics (NASDAQ:CARA) Now Covered by StockNews.com

StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report issued on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

NASDAQ CARA opened at $0.31 on Thursday. The business’s 50-day simple moving average is $0.29 and its 200-day simple moving average is $0.39. The firm has a market capitalization of $17.01 million, a P/E ratio of -0.18 and a beta of 0.68. Cara Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.31.

Institutional Investors Weigh In On Cara Therapeutics

A number of institutional investors have recently modified their holdings of CARA. Disciplined Growth Investors Inc. MN grew its stake in Cara Therapeutics by 6.6% in the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares in the last quarter. FMR LLC grew its position in shares of Cara Therapeutics by 18.5% in the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 32,789 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Cara Therapeutics in the 3rd quarter worth approximately $29,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.